NCT03955445 is a Phase 3 clinical trial of LNP023 in C3 Glomerulopathy, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT03955445?

NCT03955445 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT03955445?

Interventions in NCT03955445: LNP023.

What condition does NCT03955445 study?

NCT03955445 studies C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis.

Is NCT03955445 still recruiting?

NCT03955445 is currently recruiting now. Last updated 14 April 2026.

Last reviewed 2026-04-14 · How we verify

NCT03955445

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Recruiting now Phase 3 Last updated 14 April 2026

What this trial tests

Phase 3 trial testing LNP023 in C3 Glomerulopathy in 225 participants. Currently enrolling.

Timeline

3 October 2019

Primary endpoint
30 May 2036

30 May 2036

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	225
Start date	3 October 2019
Primary completion	30 May 2036
Estimated completion	30 May 2036
Sites	50 locations across France, Italy, Japan, Netherlands, Greece, United Kingdom, Germany, Israel

Drugs / interventions tested

LNP023 — full drug profile →

Conditions studied

C3 Glomerulopathy — all drugs for C3 Glomerulopathy →
Immune-complex-membranoproliferative Glomerulonephritis — all drugs for Immune-complex-membranoproliferative Glomerulonephritis →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 12 to 100, any sex, with C3 Glomerulopathy or Immune-complex-membranoproliferative Glomerulonephritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway.
Barratt J, Weitz I. · · 2021 · cited 88× · PMID 34566967 · DOI 10.3389/fimmu.2021.712572
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Wong E, Nester C, Cavero T, Karras A, et al · · 2023 · cited 73× · PMID 38106570 · DOI 10.1016/j.ekir.2023.09.017
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
Bomback AS, Kavanagh D, Vivarelli M, Meier M, et al · · 2022 · cited 51× · PMID 36217526 · DOI 10.1016/j.ekir.2022.07.004
Lipocalin 2-not only a biomarker: a study of current literature and systematic findings of ongoing clinical trials.
Asaf S, Maqsood F, Jalil J, Sarfraz Z, et al · · 2023 · cited 38× · PMID 36529828 · DOI 10.1007/s12026-022-09352-2
Low-molecular weight inhibitors of the alternative complement pathway.
Schubart A, Flohr S, Junt T, Eder J. · · 2023 · cited 27× · PMID 36217774 · DOI 10.1111/imr.13143
Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.
Schmidt CQ, Smith RJH. · · 2023 · cited 21× · PMID 36398537 · DOI 10.1111/imr.13164
C3 Glomerulopathy: Novel Treatment Paradigms.
Tarragon Estebanez B, Bomback AS. · · 2024 · cited 17× · PMID 38481517 · DOI 10.1016/j.ekir.2023.12.007
C3G and Ig-MPGN-treatment standard.
Noris M, Remuzzi G. · · 2024 · cited 17× · PMID 37604793 · DOI 10.1093/ndt/gfad182

Verify or expand the search:

Other trials of LNP023

Trials testing the same drug.

NCT06934967 — Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients · Phase 3 · recruiting
NCT06931691 — A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China · recruiting
NCT04557462 — A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in P · Phase 3 · recruiting
NCT04578834 — Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients · Phase 3 · completed
NCT04558918 — Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antib · Phase 3 · completed

Other recruiting trials for C3 Glomerulopathy

Currently open trials in the same condition.

NCT07156149 — Fabhalta Capsules Specified Drug-use Survey · recruiting
NCT07029542 — Home Reported Outcomes in C3G Study · recruiting
NCT06065852 — National Registry of Rare Kidney Diseases · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03955445 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 14 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03955445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing